DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…
ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage…
Results announced at the American College of Lifestyle Medicine Annual Conference in Dallas, Texas DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE)…
Teva Launches Teva Rise Teva Launches Rise - Global Open Innovation Platform First cohort features 7 real-world challenges across R&D,…
FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI),…
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…
ROCKLEDGE, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing for the…
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged…
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect…
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free…